Cutempa Medical AG startet eine der grössten MDR-konformen Studien zur Behandlung des Diabetischen Fuß-Ulcus in Deutschland

Trial StartPositive

AI Analysis

Summary

Cutempa Medical AG has initiated CURE1-DFU, one of the largest MDR-compliant studies in Germany for diabetic foot ulcer treatment, enrolling 280 patients.

Clinical Trial Data

Patients

280

Importance:3/10

Sentiment:

0.30

clinical trialdiabetic foot ulcerGermanyMDR compliantCURE1-DFU

Related Companies

$MDCE

Read the original article

Published by GlobeNewswire Clinical Studies on July 21, 2026 8:15 AM

Read Original